Carregant...

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

INTRODUCTION: Semaglutide, a new treatment option approved for the treatment of patients with type 2 diabetes mellitus, is a glucagon-like peptide-1 receptor agonist to be injected subcutaneously once weekly. This analysis used a population pharmacokinetic model of semaglutide to identify clinically...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Carlsson Petri, Kristin Cecilie, Ingwersen, Steen Hvass, Flint, Anne, Zacho, Jeppe, Overgaard, Rune Viig
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064581/
https://ncbi.nlm.nih.gov/pubmed/29907893
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0458-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!